By Eden Estopace | 2017-02-03
Intel Corporation and Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced this week a new partnership aimed at improving research and treatment for Parkinson’s disease.
The collaboration includes a multiphase research study using a new big data analytics platform that detects patterns in participant data collected from wearable technologies used to monitor symptoms.
This effort is an important step in enabling researchers and physicians to measure the progression of the disease and to speed progress toward breakthroughs in drug development.
“Nearly 200 years after Parkinson’s disease was first described by Dr. James Parkinson in 1817, we are still subjectively measuring Parkinson’s disease largely the same way doctors did then,” said Todd Sherer, PhD, CEO of The Michael J. Fox Foundation. “Data science and wearable computing hold the potential to transform our ability to capture and objectively measure patients’ actual experience of disease, with unprecedented implications for Parkinson’s drug development, diagnosis, and treatment.”
“The variability in Parkinson’s symptoms creates unique challenges in monitoring progression of the disease,” said Diane Bryant, senior vice president and general manager of Intel’s Data Center Group. “Emerging technologies can not only create a new paradigm for measurement of Parkinson’s, but as more data is made available to the medical community, it may also point to currently unidentified features of the disease that could lead to new areas of research.”
The potential to collect and analyze data from thousands of individuals on measurable features of Parkinson’s, such as slowness of movement, tremor and sleep quality, could enable researchers to assemble a better picture of the clinical progression of Parkinson’s and track its relationship to molecular changes.
Wearables can unobtrusively gather and transmit objective, experiential data in real time, 24 hours a day, seven days a week. With this approach, researchers could go from looking at a very small number of data points and burdensome pencil-and-paper patient diaries collected sporadically to analyzing hundreds of readings per second from thousands of patients and attaining a critical mass of data to detect patterns and make new discoveries.
Intel data scientists are now correlating the data collected to clinical observations and patient diaries to gauge the devices’ accuracy, and are developing algorithms to measure symptoms and disease progression.
Later this year, Intel and MJFF plan to launch a new mobile application that enables patients to report their medication intake as well as how they are feeling. The effort is part of the next phase of the study to enable medical researchers to study the effects of medication on motor symptoms via changes detected in sensor data from wearable devices.
http://www.enterpriseinnovation.net/article/intel-michael-j-fox-foundation-improve-parkinsons-disease-monitoring-1737751077
No comments:
Post a Comment